Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhertu in advanced breast cancer (DAISY)
NCT04132960Phase 2Completed
- Sponsor
- Unicancer
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in breast cancer (3 arms), sponsored by Unicancer. Primary endpoint: Objective Response Rate at 12 months. Started Oct 2019; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04132960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04132960.